Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis

X. Hong,Y. Zhang,Z. Chi, Q. Xu,W. Lin, Y. Huang,T. Lin,Y. Zhang

Clinical Oncology（2024）

Cited 0|Views20

No score

Abstract

•Efficacy and safety of PD-1/PD-L1 inhibitors in mCRPC patients was evaluated.•Thirteen studies involving 2533 participants were included in the meta-analysis.•Anti-PD-1/PD-L1 treatment may significantly increase the PFS benefits.

Translated text

Key words

Checkpoint inhibitors,meta-analysis,programmed cell death protein 1,programmed death ligand 1,prostate cancer

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined